Section Arrow
ORIC.NASDAQ
- Oric Pharmaceuticals
Quotes are at least 15-min delayed:2025/07/22 16:14 EDT
After Hours
Last
 11.15
0 (0.00%)
Bid
6
Ask
12
High 11.15 
Low 11.15 
Volume 7177 
Regular Hours
Last
 11.15
+0.09 (+0.81%)
Day High 
11.4 
Prev. Close
11.06 
1-M High
11.5699 
Volume 
548.69K 
Bid
6
Ask
12
Day Low
11.0209 
Open
11.08 
1-M Low
9.105 
Market Cap 
942.52M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.01 
20-SMA 10.7 
50-SMA 8.72 
52-W High 14.67 
52-W Low 3.8951 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.88/-1.85
Enterprise Value
942.52M
Balance Sheet
Book Value Per Share
2.58
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.053+0.002+3.92%-- 
After Hours 0.05325 +0.00025 +0.47%
PLRZPolyrizon Ltd1.45+0.5422+59.73%-- 
After Hours 1.63 +0.18 +12.41%
REPLReplimune Group2.805-9.52-77.24%-- 
After Hours 2.83 +0.025 +0.89%
IOVAIovance Biotherapeutics3.13+0.64+25.70%-- 
After Hours 3.1694 +0.0394 +1.26%
TNFATNF Pharmaceuticals Inc.0.107-0.0224-17.31%-- 
After Hours 0.1059 -0.0011 -1.03%
Quotes are at least 15-min delayed:2025/07/22 16:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.